Veterinary Immunodiagnostics Market by Product (Analyzers, Consumables {Leukemia, Influenza, BTV, FMD, BTB, BHV}), Animal (Livestock, Companion), Technology (ELISA, Radioimmunoassay, Rapid Tests), End User (Hospital, Point-of-care) - Global Forecast to 2029

The Veterinary Immunodiagnostics Market is expected to record a CAGR of 9.3% during the forecast period 2022–2029 to reach $2.71 billion by 2029. The growth of this market is driven by the increasing prevalence of diseases in animals, the presence of disease-specific immunodiagnostic tests, and advancements in immunodiagnostic technology. Moreover, the increasing pet population and the rising demand for animal-derived foods support the growth of this market. Emerging economies are expected to create opportunities for the growth of this market.

However, inadequate veterinary diagnostics infrastructure in developing countries is expected to remain a major challenge to the growth of the veterinary immunodiagnostics market.

The Impact of Covid-19 On The Veterinary Immunodiagnostics Market

COVID-19 virus is a zoonotic disease, i.e., it emerged from an animal source. This has led to increased awareness among people regarding the health hazards of animals and animal-derived food products. Moreover, there were cases of COVID-19 infections in pets in several countries. These infected pets were found to be living with COVID-19-positive humans. For instance, in June 2020, the United States Department of Agriculture’s National Veterinary Services Laboratories (USDA NVSL) announced the first confirmed case of COVID-19 infection in a pet dog (German shepherd) in New York state. In response to these incidents, authorities such as the Centers for Disease Control and Prevention (CDC), in 2020, issued testing guidelines for companion, livestock, zoo, and wild animals for epidemiological investigations. Moreover, scientists and researchers studied test kits for detecting COVID-19 infections in animals.

The pandemic had a mixed impact on the veterinary immunodiagnostics market. On one hand, it opened new opportunities for the development and research of tests for diagnosing COVID-19 infections in animals and increased awareness among people regarding the importance of animal diagnostics and health. On the other hand, the pandemic disrupted the supply chain leading to decreased consumption of animal-derived products. Travel restrictions further made it difficult for the companies and laboratories to procure, dispatch, and ship laboratory tools and equipment. However, this negative impact is expected to last for a short duration as the world is recovering from the pandemic and consuming animal-derived food products is resumed.

Click here to: Get Sample Pages of this Report 

Increasing Prevalence of Diseases in Animals

Several research studies have established the relation between zoonotic infections and global human outbreaks, the recent being SARS-CoV-2 (COVID-19 virus) pandemic. Early disease diagnosis and treatment in animals are crucial to avoid the spread of such infections in the future. As animals provide food for consumption, foodborne zoonotic diseases are caused by consuming food or water contaminated by pathogenic microorganisms. For instance, according to CDC, in 2020, nearly 18,462 cases of foodborne disease infections were witnessed in the U.S., including 4,788 hospitalizations and 118 deaths. The World Health Organization (WHO) states that the total productivity loss associated with foodborne disease in low-and middle-income countries was $110 billion in 2020.

Zoonotic Tuberculosis (TB) remains a poorly addressed and monitored disease in developing and underdeveloped countries. For instance, according to the WHO, in 2019, 140,000 new cases of zoonotic TB occurred globally, resulting in approximately 11,400 deaths. Africa carries the heaviest burden of disease and death due to zoonotic TB, followed by Southeast Asia.

Diabetes mellitus & heartworm disease are the most common diseases diagnosed in canines and felines. Diabetes Mellitus is a chronic disease that requires long-term monitoring and management. According to the 2019 Banfield Pet Hospital Report, there was a 79.7% increase in dogs with diabetes between 2006 and 2018, with 23.6 cases per 10,000 dogs. Similarly, the incidence of feline diabetes increased by 18.1% from 2006 to 2018, which is 67.6 cases per 10,000 cats.

Key Findings of The Veterinary Immunodiagnostics Market Study:

The Consumables Segment to Dominate the Veterinary Immunodiagnostics Market in 2022

The increased prevalence of zoonotic diseases among animals and the risk of infections crossing the species barrier and infecting humans drive the growth of this segment.

The ELISA Segment to Account for the Largest Market Share by 2029

The large market share of this segment is attributed to the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA.

The Livestock Segment to Account for the Largest Market Share by 2029

The factors contributing to the growth of this segment are increasing demand for food production across the globe and awareness about animal health.

Asia-Pacific to Be the Fastest Growing Regional Market

In 2022, North America is expected to dominate the veterinary immunodiagnostics market, while Asia-Pacific is expected to record the highest CAGR during the forecast period. The high growth of the Asia-Pacific veterinary immunodiagnostics market is attributed to a large population of livestock and the rising incidence of various zoonotic diseases in the region.

Key Players

The report includes a competitive landscape based on the extensive assessment of the product portfolios, geographic presence, and key strategic developments of leading market players over the last four years. The key players profiled in the veterinary immunodiagnostics market are IDEXX Laboratories, Inc. (U.S.), Zoetis Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Virbac (France), Heska Corporation (U.S.) Randox Laboratories, Ltd (U.S.), Neogen Corporation (U.S.), QIAGEN N.V. (Germany), Abaxis, Inc. (U.S.), and bioMérieux S.A. (France).

Scope of the Report:

Veterinary Immunodiagnostics Market, by Product

• Analyzers
• Consumables
  • Heartworm
  • Leukemia
  • Bovine Viral Diarrhea
  • Influenza
  • Foot & Mouth Disease
  • Blue Tongue
  • Bovine Tuberculosis
  • Bovine Herpes Virus
  • New Castle Disease
  • Avian Mycoplasma
  • Other Diseases
    (Other Diseases include Equine Piroplasmosis, Infectious Bronchitis Virus, Bovine Spongiform Encephalopathy, Porcine Respiratory & Reproductive Syndrome, Leptospirosis, Parvovirus, and Others)

Veterinary Immunodiagnostics Market, by Technology

• ELISA
  • Chemiluminescence Immunoassays
  • Fluorescent Immunoassays
  • Colorimetric Immunoassays
• Radioimmuno Assays
• Rapid tests
• Other Technologies
  (Other Technologies include Virus neutralization, hemagglutination inhibition, and HPLC) 

Veterinary Immunodiagnostics Market, by Animal Type

• Companion Animals
  • Canine
  • Feline
  • Other Companion Animals
• Livestock
  • Ruminants
  • Swine
  • Poultry
  • Others

Veterinary Immunodiagnostics Market, by End User

• Reference Laboratories
• Veterinary Hospitals & Clinics
• PoC Testing

Veterinary Immunodiagnostics Market, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • Australia
  • Rest of APAC (RoAPAC)
• Latin America
• Middle East & Africa

Key Questions Answered in the Report: